// App-Quantinova.ai

: Safety and efficacy from the phase 1 SURPASS trial of ADP-A2M4CD8, a next-generation T-cell receptor T-cell therapy, in patients with advanced esophageal, esophagogastric junction, or gastric cancer.

Researchers

Presenter

  • Mariela A. Blum Murphy

Principal Investigators

  • Jaffer A. Ajani

  • Brian Andrew Van Tine

  • Jeffrey Melson Clarke

  • Marcus O. Butler

  • Donald P. Lawrence

  • Melissa Lynne Johnson

  • Andres Cervantes

  • Victor Moreno

  • David S. Hong

  • Francine Elizabeth Brophy

  • Jean-Marc Navenot

  • Quan Lin

  • Jose Saro

  • Elliot Norry

Medical Centers

  • Washington University School of Medicine, St. Louis, MO

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Biomedical Research Institute INCLICA, University of Valencia, Valencia, Spain

  • Adaptimmune, Abingdon, United Kingdom

  • Adaptimmune, Philadelphia, PA

  • Sarah Cannon Research Institute, Nashville, TN

  • Medical Oncology, START Madrid-FJD, Fundación Jiménez Díaz Hospital, Madrid, Spain

  • Duke Cancer Institute, Durham, NC

  • Massachusetts General Hospital, Boston, MA

  • Princess Margaret Cancer Center, Toronto, ON, Canada

Locations

  • Spain

  • United Kingdom

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Gastric Cancer

Biomarkers

  • T-cell receptor

Drug/Treatment

  • Surpass Cream

Outcome

  • N/A

Study Design

  • Dose Escalation

  • Cohort

  • First-In-Human

Phase

  • I

Study Id's

  • NCT04044859

  • NCT04752358

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved